E-LIB Suche - Ergebnisse für: Lonial, S.

1

Phase 2 Trial of Anti-PD1 and 8 Gy in 1 Fraction for Relaps..:

Khan, M.K. ; Nasti, T. ; Kleber, T....
International Journal of Radiation Oncology*Biology*Physics. 117 (2023) 2 - p. S108 , 2023

Link: https://doi.org/10.1016/..

2

P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELA..:

Nooka, A. ; Cohen, A. ; Lee, H....
HemaSphere. 7 (2023) S2 - p. 27-28 , 2023

Link: https://doi.org/10.1097/..

3

P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF..:

van de Donk, N. W. C. J ; Popat, R ; Hulin, C...
HemaSphere. 6 (2022) - p. 14-15 , 2022

Link: https://doi.org/10.1097/..

4

P1739: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH TRIP..:

van de Donk, N. W. ; Guo, S. ; Shi, L....
HemaSphere. 6 (2022) - p. 1620-1621 , 2022

Link: https://doi.org/10.1097/..

5

P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFI..:

Popat, R ; Badros, A ; Kumar, S...
HemaSphere. 6 (2022) - p. 18-18 , 2022

Link: https://doi.org/10.1097/..

6

P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN ..:

Nooka, A. ; Lonial, S. ; Grosicki, S....
HemaSphere. 6 (2022) - p. 829-830 , 2022

Link: https://doi.org/10.1097/..

7

P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IB..:

Amatangelo, M. ; Cheng, Y. ; Pierceall, W....
HemaSphere. 6 (2022) - p. 758-759 , 2022

Link: https://doi.org/10.1097/..

8

P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VIC..:

Rodríguez-Otero, P ; San-Miguel, J ; Anderson, LD...
HemaSphere. 6 (2022) - p. 22-23 , 2022

Link: https://doi.org/10.1097/..

9

PB1983: TRIAL-IN-PROGRESS: PHASE II STUDY OF PHE885, A B-CE..:

Munshi, N. ; Spencer, A. ; Raab, M. S....
HemaSphere. 6 (2022) - p. 1855-1856 , 2022

Link: https://doi.org/10.1097/..

10

Correction: Pomalidomide, bortezomib, and low-dose dexameth..:

Richardson, P. G. ; Hofmeister, C. C. ; Raje, N. S....
Leukemia. 32 (2018) 10 - p. 2305-2305 , 2018

Link: https://doi.org/10.1038/..

11

High somatic mutation and neoantigen burden are correlated ..:

Miller, A ; Asmann, Y ; Cattaneo, L...
Blood Cancer Journal. 7 (2017) 9 - p. e612-e612 , 2017

Link: https://doi.org/10.1038/..

12

Phase I/II trial of the oral regimen ixazomib, pomalidomide..:

Krishnan, A ; Kapoor, P ; Palmer, J M...
Leukemia. , 2017

Link: https://doi.org/10.1038/..

13

Pomalidomide, bortezomib and low-dose dexamethasone in lena..:

Richardson, P G ; Hofmeister, C C ; Raje, N S...
Leukemia. 31 (2017) 12 - p. 2695-2701 , 2017

Link: https://doi.org/10.1038/..

14

14-3-3ζ binds the proteasome, limits proteolytic function a..:

Gu, Y ; Xu, K ; Torre, C...
Leukemia. 32 (2017) 3 - p. 744-751 , 2017

Link: https://doi.org/10.1038/..

15

Integrative network analysis identifies novel drivers of pa..:

Laganà, A ; Perumal, D ; Melnekoff, D...
Leukemia. 32 (2017) 1 - p. 120-130 , 2017

Link: https://doi.org/10.1038/..